New study aims to match pancreatic cancer patients with best chemo

NCT ID NCT04469556

Completed Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested two standard chemotherapy regimens, Folfirinox and Gemcitabine/nab-paclitaxel, in 150 patients with untreated metastatic pancreatic cancer. The goal was to see which works better and to use lab tests to personalize treatment. The study is complete, and results may help guide future therapy choices.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Folfirinox and Gemcitabine/nab-paclitaxel (chemotherapy)
What this could lead to: If successful, this could help doctors choose the best chemotherapy for each patient with advanced pancreatic cancer, potentially improving survival.
What could go wrong: This is a mid-stage trial with 150 participants, so results may not apply to everyone. Chemotherapy has significant side effects, and the study may not show a clear benefit for either drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED PANCREATIC CANCER PANCREATIC CANCER METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

BC Cancer Agency Vancouver

Vancouver, British Columbia, V5Z 1L8, Canada
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Baltimore, Maryland, 21231, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Northwell Health

New Hyde Park, New York, 11042, United States
Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2N9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.